Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015
August 14, 2015 at 05:03 pm EDT
Share
Arno Therapeutics, Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations was $3,979,000 compared to $5,763,000 a year ago. Net loss was $3,445,000 or $0.17 per diluted share compared to net income of $3,495,000 or $0.14 per diluted share a year ago. Non GAAP adjusted net loss was $3,033,000 or $0.15 per basic share compared to $4,528,000 or $0.22 per basic share a year ago.
For the six months, the company reported loss from operations was $7,842,000 compared to $11,927,000 a year ago. Net loss was $6,834,000 or $0.33 per diluted share compared to net income of $3,048,000 or $0.12 per diluted share a year ago. Non GAAP adjusted net loss was $5,898,000 or $0.29 per basic share compared to $9,517,000 or $0.47 per basic share a year ago.
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
ARNO THERAPEUTICS, INC. 
